ArticleBMJ open2026
Comprehensive proteomic classifier for molecular characterisation of pulmonary sarcoidosis: protocol for a longitudinal multi-centre study to evaluate bronchoalveolar fluid and cell diagnostic and prognostic biomarkers of pulmonary sarcoidosis.
Article in BMJ open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
introductionSarcoidosis is a multisystem disorder with variable presentation and disease course. Diagnosis requires the exclusion of other causes of granulomatous inflammation. Current clinical management is often fraught with diagnostic uncertainy and the lack of tools to predict pulmonary disease progression. To address these challenges, we designed a study using data from bronchoalveolar lavage (BAL) fluid and cells to develop diagnostic and prognostic tools in patients with pulmonary sarcoidosis. METHODS AND ANALYSIS: This multicentre study will include discovery and validation cohorts of healthy controls, interstitial lung disease controls and pulmonary sarcoidosis cases from three study sites. Sarcoidosis participants will be grouped into progressive and non-progressive pulmonary disease based on changes in pulmonary function testing, chest radiographs or treatment requirements. The discovery cohort consists of participants with existing BAL fluid, BAL cells, and clinical datasets; the validation cohort will be prospectively enrolled and participants will consent for BAL collection from either a clinical or research bronchoscopy. Untargeted proteomic profiling of BALF along with statistical modelling with variable selection techniques will generate a classifier for diagnosis and prognosis. Targeted proteomics using parallel reaction monitoring-mass spectrometry will be used for internal and external validation. Additionally, BAL cell single-cell gene-expression analysis using Cellular Indexing of Transcriptomes and Epitopes by Sequencing (CITE-seq) will be integrated with proteome-wide data to elucidate cell-specific pathways implicated in the development and progression of sarcoidosis. ETHICS AND DISSEMINATION: The study will be conducted in accordance with Good Clinical Practice and the Declaration of Helsinki. The protocol has been approved by the Biomedical Research Alliance of New York Institutional Review Board (IRB), which serves as the single IRB across all study sites. The findings of this study will be presented as abstracts at scientific meetings and summarised in peer-reviewed journal manuscripts.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.